News|Articles|November 16, 2026

Morning Rounds: News From November 9-16

Listen
0:00 / 0:00

Key Takeaways

  • HLP003 adjunctive therapy produced a 7.6-point placebo-adjusted MADRS reduction at week 6 (P<0.0001), separating by day 2 and maintaining benefit through week 12.
  • Week 6 clinical outcomes favored HLP003, with response 56.3% versus 28.2% and remission 50.9% versus 18.2%, while three treatment-related serious adverse events were reported.
SHOW MORE

Review news from the last week in pharmacology, legislation, and research.

HLP003 Reduces Depression in Phase 3 Adjunctive Trial

Helus Pharma announced positive topline results from APPROACH, a Phase 3 trial of HLP003 (deuterated psilocin) added to a stable antidepressant in 222 adults with moderate-to-severe major depressive disorder (112 HLP003, 110 placebo). At week 6, Montgomery-Åsberg Depression Rating Scale scores fell 19.5 points with HLP003 versus 11.9 with placebo, a placebo-adjusted difference of 7.6 points (P<0.0001). Separation appeared by day 2 (5.0 points) and persisted at week 12 (7.0 points). Week 6 response was 56.3% versus 28.2%, and remission was 50.9% versus 18.2%. Most adverse events were mild to moderate and confined to dosing day, though 3 treatment-related serious adverse events occurred.¹

FDA Approves Igalmi as First At-Home Treatment for Agitation in Schizophrenia and Bipolar Disorder

The US Food and Drug Administration (FDA) approved Igalmi (dexmedetomidine) sublingual film for at-home use in adults with agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder, expanding a product previously limited to supervised settings. Approval rests on the Phase 3 SERENITY At-Home trial, a 12-week randomized, double-blind, placebo-controlled study of 102 patients covering 1,160 treated agitation episodes, which met its primary endpoint of at-home safety and tolerability. Common adverse events (at least 5% and greater than placebo) were somnolence, dry mouth, dizziness, and oral paresthesia or hypoesthesia. Labeling warns of hypotension, orthostatic hypotension, and bradycardia, with interaction risk for blood pressure and heart medicines, sedatives, and opioids.²

Compass Pathways Completes COMP360 Psilocybin Application for Treatment-Resistant Depression

Compass Pathways completed its New Drug Application with the FDA for COMP360, a synthetic psilocybin formulation, for treatment-resistant depression. The submission draws on 2 phase 3 trials and 1 phase 2b study enrolling more than 1000 participants combined, all of which the company reports met their primary endpoints. COMP360 holds a National Priority Voucher and rolling review that could shorten the FDA timeline, though the company cautions that neither guarantees faster review or approval. Because COMP360 contains a Schedule I controlled substance, the Drug Enforcement Administration and individual states would need to reschedule it before commercialization, but the initial approval and timing of subsequent decisions is uncertain.

FDA Reportedly Shelves Commissioner's Voucher Program for Speedy Drug Reviews

The FDA has shelved the Commissioner's National Priority Voucher program launched in June 2025 under former Commissioner Marty Makary. No new vouchers have been issued since Makary left in May, and the political appointee council that oversaw reviews has reportedly gone dormant. Of 22 drugs awarded vouchers, about a dozen were approved, some 8 or more months sooner than standard review. Sponsors were reportedly told they may keep submitting but that applications will not advance, while a US Department of Health and Human Services spokesperson said the pilot is ongoing.⁴ Nine drugs remain in the program, including COMP360 and PSIL201 (psilocybin) for treatment-resistant depression and major depressive disorder, respectively, and TSND-201 (methylone) for posttraumatic stress disorder, and 2 sources say FDA career scientists have resumed overseeing their review timelines.

Roluperidone Data Show Modest Negative Symptom Separation From Placebo in Sponsor-Hosted Review

Minerva Neurosciences hosted a review of roluperidone, an investigational agent for negative symptoms of schizophrenia that lacks direct dopamine blockade, with activity attributed to 5-HT2A antagonism, sigma-2 receptor activity, and alpha-1 adrenergic activity. In the phase 2b MIN-101C03 study, the 64 mg dose separated from placebo on the Marder negative symptom factor score, while separation in the phase 3 MIN-101C07 study was smaller; Personal and Social Performance scale scores improved versus placebo in both. Primary negative symptoms improved versus placebo (P = 0.03), whereas secondary negative symptoms did not differ (P = 0.61). About 38% of roluperidone patients versus about 22% of placebo patients achieved at least a 20% negative symptom improvement, with numbers needed to treat of 7, 8, and 9 across responder analyses. Presenters said the target population, with high negative and low positive symptoms, carries a lower relapse risk regardless of treatment.⁵

References

1. Helus Pharma announces positive topline results from phase 3 APPROACH study evaluating HLP003 as adjunctive treatment in major depressive disorder. Press release. November 16, 2026. Accessed November 16, 2026. https://www.globenewswire.com/news-release/2026/11/16/3403358/0/en/helus-pharma-announces-positive-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder.html

2. US FDA approves Igalmi as first at-home acute treatment for agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder in adults. Press release. November 16, 2026. Accessed November 16, 2026. https://www.globenewswire.com/news-release/2026/11/16/3403459/0/en/u-s-fda-approves-igalmi-as-first-at-home-acute-treatment-for-agitation-associated-with-schizophrenia-schizoaffective-disorder-or-bipolar-i-or-ii-disorder-in-adults.html

3. Compass Pathways completes COMP360 psilocybin new drug application to US FDA for treatment-resistant depression. Press release. November 9, 2026. Accessed November 16, 2026. https://via.ritzau.dk/pressemeddelelse/15277398/compass-pathways-completes-comp360-psilocybin-new-drug-application-to-us-fda-for-treatment-resistant-depression?publisherId=90456

4. Wingrove P, Abutaleb Y. US FDA shelves commissioner's voucher program for speedy drug reviews, sources say. Reuters. November 12, 2026. Accessed November 16, 2026. https://www.reuters.com/world/us-fda-shelves-commissioners-voucher-program-speedy-drug-reviews-sources-say-2026-11-12/

5. Walters J. Reviewing roluperidone as treatment for negative symptoms in schizophrenia. Psychiatric Times. November 12, 2026. https://www.psychiatrictimes.com/view/reviewing-roluperidone-as-treatment-for-negative-symptoms-in-schizophrenia


Related to this article